Sharing Expertise: AMGA Roundtable-Wellness Initiatives at Summit CityMD
On Wednesday, April 15, Summit Medical Group Chief of Behavioral Health and Wellness, Dr. James Korman, along with Senior Vice President of Medical Affairs and Quality, Dr. Ashish Parikh, hosted a roundtable for the Chief Medical Officers Council and Quality Council of the American Medical Group Association (AMGA) on Wellness Initiatives for Providers and Staff During the COVID-19 Crisis. Dr. Parikh moderated while Dr. Korman presented the notable work Summit Medical Group is doing to maintain the well-being of our staff and providers during this difficult time. The presentation—met with great acclaim and later shared with all AMGA providers—included information on our behavioral health services and wellness program initiatives as well as strategies in place to address current stressors.
Physician Leadership and Innovation During Coronavirus Crisis
Despite being deeply entangled in the biggest health care crisis of our time, our doctors continue to lead the way, not only guiding patients and staff through this difficult period but also sharing our health care delivery successes with others to help address the needs of a broader health system.
On March 26, the National Association of ACOs (NAACOs) hosted Webinar Today: New Telehealth Flexibilities, a panel presentation where panelists, including our own Dr. Ashish Parikh, discussed technology’s critical role in direct patient care and how providers are implementing new digital processes to combat the coronavirus crisis. In his presentation, Dr. Parikh covered details such as expanded telehealth benefits under the Trump administration and SMG’s rapid adoption of virtual visits, which has the potential to minimize the burden on emergency departments and hospital systems. The following day, Dr. Parikh presented on the role medical groups can play in supporting the healthcare system during this pandemic alongside Scott Hines, MD, Crystal Run Healthcare's Chief Quality Officer, on an American Medical Group Association (AMGA) Quality Council panel focused on medical group response to COVID-19.
We’re beyond proud that even during such a chaotic and uncertain time, especially for our industry, our organization and its devoted employees do not seem to miss a beat.
“The Show Must Go On!”: Arcadia and Its Customers Create a Virtual Conference to Demonstrate How to Make Value-based Care Profitable
After cancelation of largest healthcare technology show, analytics leader plans for customers to speak about improved performance in value-based payment models
Burlington, Mass.—March 10, 2020—Arcadia (arcadia.io), a widely-recognized leader in population health management, today announced the launch of “Arcadia’s Value-Based Care Leadership Series” to provide a virtual conference to ensure HIMSS attendees, as well as others, will still be able to attend the six general education sessions from their notable and innovative clients. This virtual conference will feature presentations by the leaders in value-based care who were scheduled to present at HIMSS20.
“Arcadia is proud that our innovative provider clients were recognized by HIMSS to deliver sessions about how they’ve successfully navigated value-based payment models,” said Arcadia chief executive officer Sean Carroll. “These customers have agreed to provide their experiences and successes, in a virtual format, over the next few weeks because they are eager to share with peers how to overcome the uncertainty of transitioning from volume-based to value-based care. The honors they were recognized for by HIMSS highlight Arcadia’s dedication to partnering with them and helping to succeed in the evolution of healthcare delivery.”
The virtual conference will feature seven separate webinars and will kick off on Wednesday, March 11 at 11:15 am Eastern with a lunch-and-learn webinar featuring Dr. John Halamka of the Mayo Clinic. Dr. Halamka, who is known for his work at the forefront of technology-enabled care delivery and serves as president of Mayo Clinic Platform, a digital health initiative designed to transform care delivery, will discuss his thoughts on the state of digital health.
Following the initial webinar on March 11, Arcadia will conduct a new webinar almost every week throughout March, April and May. Healthcare leaders will share their strategies in achieving success and the importance of data and analytics technology in the transition to value-based payment models. The following provides additional information about the virtual lunch-and-learn as well as upcoming webinars. For virtual session dates and times, and to register, please visit https://www.arcadia.io/about-arcadia/vbc-leadership-series/.
- Summit Medical Group will deliver two webinars:
- Drs. Jamie L. Reedy and Amina A. Ahmed will present “Using Analytics to Drive Patient-Centered Post-Acute Care” which will demonstrate how Summit has achieved success by implementing technology to support care coordination and monitor performance across care settings in order to reduce their year-over-year length of stay metrics for skilled nursing facilities.
- Drs. Jamie L. Reedy and Ashish D. Parikh will present “Commercial Risk: Getting off to a Successful Start” which will illustrate how Summit has aligned incentives with a data-driven education program for both clinicians and staff to deliver patient-centric, high quality care while succeeding in seven value-based contracts.
- Community Health Plan of Washington will present “Capturing SDoH Data Across Community Health Centers” which will address how to engage and partner with providers to capture and work with SDoH data to enable community partners and community health centers to mobilize resources.
- Central Georgia Health Network will present “Helping PCPs Transition to New Payment Models” which will explain how they prepared a large, diverse clinically integrated network to deal with changing payment models.
- MaineHealth Accountable Care Organization will present “Tackling Emergency Department Utilization with Predictive Analytics” to showcase how emergency departments (EDs) can reduce unnecessary utilization with predictive analytics and will look at how the organization launched REDUCE (Reducing ED Utilization: A Collaborative Endeavor) to address the high rates of ED utilization (one of the highest in the nation) in 10 regions in Maine.
- AMITA Health will present “Rewarding Value: Realigning Physician Compensation” which will look at how AMITA has used analytics and behavioral economics to incentivize high quality and efficient care. In addition, the webinar will review strategies for engaging physicians in value-based transformation and the importance of clinical integration as a vehicle for crafting virtually integrated delivery systems.
Arcadia (arcadia.io) is the only healthcare data and software company dedicated to healthcare organizations achieving financial success in value-based care. We work with health systems, providers, payers and life science companies positioning themselves to win in value-based care, including some of the largest, most complex and influential health systems in the country. Through our purpose-built population health platform our customers consistently overperform industry average outcomes by reducing medical expenses, improving risk coding accuracy, and improving quality and patient health outcomes. Our software continuously aggregates and curates the highest quality, most complete and up-to-date data foundation; provides relevant, timely and predictive analytics; and enables action through care management tools and in-workflow insights that present at the point of care. Arcadia has off-the-shelf integration technology for more than 50 different physical and behavioral health EHR vendors, powered by machine learning that combs through variations in over 77 million longitudinal patient records across clinical, claims, social determinants of health and operational data sources. Founded in 2002, Arcadia is headquartered outside Boston in Burlington, MA, with offices in Seattle, Pittsburgh, Chicago, and Rockford, IL. Arcadia has been recognized as the leading vendor by Forrester, IDC, Chilmark and KLAS, including being awarded Best in KLAS for Value-Based Care Managed Services in 2019 and again in 2020.
Nicole Rodriguez, Senior Account Director, Amendola Communications for Arcadia
Catheter ablation with renal denervation may eliminate AF at 12 months
Renal denervation with catheter ablation in patients with paroxysmal atrial fibrillation and hypertension significantly increased the likelihood of freedom from AF at 12 months compared with catheter ablation alone, according to results of the ERADICATE-AF trial published in JAMA.
The publication confirms findings previously presented at the Heart Rhythm Society Annual Scientific Sessions in 2019.
“The results of this study provide strong proof that renal denervation can augment the results of standard catheter ablation for AF and suggest that a strategy of incorporating autonomic modulation is a useful approach to arrhythmia control independent of direct targeting of cardiac tissue,” Jonathan S. Steinberg, MD, FHRS, adjunct professor of medicine at the University of Rochester School of Medicine and Dentistry and director of SMG Arrhythmia Services at Summit Medical Group of New Jersey, told Healio.
AF and hypertension
Researchers analyzed data from 302 patients (median age, 60 years; 60% men) with a history of symptomatic paroxysmal AF, a history of clinically significant hypertension and plans to undergo ablation. Patients were assigned catheter ablation using pulmonary vein isolation alone (n = 148) or with renal denervation (n = 154).
The primary endpoint was freedom from AF recurrence at 12 months without taking antiarrhythmic drugs. Several secondary endpoints were assessed including mean systolic BP and procedural complications.
Patients attended follow-up visits at 1 month, 3 months, 6 months, 9 months and 12 months. Treatment failure was defined as the initiation of antiarrhythmic drugs or repeat ablation procedures.
The majority of patients (93.7%) completed the trial, and all patients successfully underwent assigned procedures.
At 12 months, freedom from AF, atrial flutter or atrial tachycardia occurred in 56.5% of patients assigned pulmonary vein isolation alone vs. 72.1% of those assigned pulmonary vein isolation with renal denervation (HR = 0.57; 95% CI, 0.38-0.85).
From baseline to 12 months, mean systolic BP decreased from 151 mm Hg to 147 mm Hg in patients assigned pulmonary vein isolation only. By contrast, patients assigned pulmonary vein isolation plus renal denervation had a decline in systolic BP from 150 mm Hg to 135 mm Hg (between-group difference = 13 mm Hg, 95% CI, 15 to 11; P < .001).
Procedural complications occurred in 4.7% of patients in the isolation-only group vs. 4.5% of those in the renal denervation group (absolute risk difference = 0.1%; 95% CI, 4 to 4.4; P > .99).
“We have designed additional trials to expand the potential universe of patients who may be eligible to the approach used in this trial,” Steinberg said in an interview. “Our highest priority are patients with persistent AF as well as controlled hypertension or absence of hypertension.”
Steinberg added that the absence of a sham-controlled group in this trial does not detract from the findings “because patients were fully sedated and completely unaware of which procedure was being performed (or whether an arterial puncture or renal angiogram was done.”
A Cohort Study of the Exhalation Delivery System with Fluticasone for Chronic Sinusitis with or without Nasal Polyps
Inhaled nasal corticosteroid sprays (INS) are often inadequate to treat chronic rhinosinusitis (CRS). The exhalation delivery system with fluticasone (EDS-FLU; XHANCE®) may improve outcomes in CRS by increasing medication delivery to target superior/posterior anatomic sites. This study assessed safety and efficacy of EDS-FLU in a large population with moderate-to-severe CRS with or without nasal polyps (CRSwNP, CRSsNP).
National VP of Pharmacy Services, Dr. Laura Balsamini; panelist at the 69th Annual Roy A. Bowers Pharmaceutical Conference
Pharmacy Cost and Transparency: Understanding Trend Drivers, Finding Solutions to Rising Costs, and Supporting Sustainability of the Benefit Program, Transitions of Care, Episodes of Care, and Continuity of Care
National VP of Pharmacy Services, Dr. Laura Balsamini was a panelist at the 69th Annual Roy A. Bowers Pharmaceutical Conference held at The Palace in Somerset, NJ on November 18th. This year’s theme was Pharmacy Cost and Transparency. Dr. Balsamini was part of an esteemed panel of pharmacy leaders who discussed trend drivers, solutions to rising costs, sustainability of the benefit program, transition of care, and continuity of care. Specialty Pharmaceuticals took the center stage of discussion given they account for 50 percent of total U.S. drug spend and are used by only 1 percent of the patient population. Dr. Balsamini shared strategies to mitigate specialty pharmacy related costs that include addressing infusion site of care, increased biosimilar utilization and having Clinical Specialty Pharmacists participating in the monitoring, delivery and management of these agents to improve patient outcomes.
Dr. Kenneth Adler Chairs Cancer Research Symposium
The New Jersey Commission on Cancer Research Annual Symposium, chaired by SMG Oncologist, Dr. Kenneth Adler, was held on Thursday, November 7 at Rider University. 30 poster presentations were given by doctoral students throughout the state addressing basic science research in cancer, and a keynote speech was shared by Dr. Arnold Rabson of Rutgers on retroviruses and cancer. The audience included many members of the Department of Health and others dedicated to the field of hematology/oncology. Additional highlights included an employment panel for graduate students, recognition of Dr. Michael Gallo and Senator Steve Sweeney for their support of cancer research, and a Patient Advocate Award presented to cancer survivor, Debby Madiraca by Dr. Grana of Cooper University Health Care.
Reducing Cardiovascular Risk for Adults with Type 2 Diabetes
As a group who strives to be a leader in cardiovascular management, SMG is proud to have recently completed AMGA’s year-long quality improvement initiative, the Together 2 Goal® Innovator Track Cardiovascular Disease Cohort (CVD Cohort), as one of only 12 medical groups and health systems chosen to identify and implement a number of interventions with the goal of lowering CVD risk in Type 2 diabetes patients. To measure intervention effectiveness, SMG and other participants submitted baseline and quarterly data on smoking cessation, lipid management, and appropriate regimentation of high intensity statin and daily aspirin—measures selected for relevance to CVD risk. Overall, participants saw improvement in every area.
SMG implemented four concurrent interventions: 1. Establish a registry of Type 2 diabetes (diabetes) patients at risk for CVD; 2. Implement the atherosclerotic CVD (ASCVD) calculator into the electronic health record (EHR); 3. Provide statin and aspirin education to providers and patients; 4. Maintain high levels of achieved cessation in tobacco users.
To achieve these interventions, SMG formed a multidisciplinary committee to lead the project and to take responsibility for patient outreach and in-office patient contact. SMG improved its performance in four of the six selected CVD Cohort measures, including a 1.5% increase in high intensity statin use among the high-risk patient population. SMG also maintained a very high level of tobacco non-use at 92.5%.
SMG’s case study project team included National VP, Pharmacy Services, Dr. Laura Balsamini, cardiologist, Liana Spano-Brennan, DO, National Director of Quality Improvement, Debbie Molina, and Population Health Project Coordinator’s, Yudine Louis-Juste and Laurie Kerrigan. Both Drs. Balsamini and Spano-Brennan also served on the Cohort’s Advisory Board. “Millions of Americans are living with Type 2 diabetes which means they are also at risk for high blood pressure, high blood sugar, and obesity which increases their risk for CVD,” says Dr. Balsamini. “For us, this Cohort proved that even the smallest changes in practice can make a major difference and we’re so grateful to have had an opportunity to explore how our providers can better identify and manage CVD risk among our diabetic population,” she adds.
National Day of Action T2G Talk & Taste
AGMA’s Together 2 Goal® (T2G) campaign aims to improve care for those living with type 2 diabetes. T2G campaign participants aim to improve standard type 2 diabetes measures, including blood sugar control, blood pressure control, lipid management, and testing for kidney disease. Over the past year, the campaign expanded its focus to explore other areas of treatment and measurement that could improve outcomes for patients with diabetes, including addressing risk of cardiovascular disease.
Each year, the campaign hosts a “National Day of Action”—a day when health professionals across the country come together to take steps to improve diabetes care. For two consecutive years, SMG was happy to get in on the action! On November 14, SMG assembled the committee which has been working to advance diabetes improvement efforts, to participate in AMGA’s “T2G Talk & Taste” event. Gathered over breakfast, they discussed T2G’s application in helping to motivate patients to take control of their diabetes.
A special congratulations to SMG Cardiologist, Liana Spano-Brennan, DO for being chosen this year by AMGA as a Plank Mentor. Plank Mentors are individuals chosen for excelling at implementing a given campaign plank within their organization and are available to fellow campaign participants to answer questions, offer expertise, and share lessons learned in a one-on-one setting. Dr. Spano-Brennan was elected for successfully assessing and addressing risk of cardiovascular disease in patients.
Drs. Laura Balsamini and Brian Freed Complete New Jersey Healthcare Executives Leadership Academy
Summit Medical Group’s Laura Balsamini, PharmD, National Vice President of Pharmacy Services, and Brian Freed, DO, Interventional Pain Management specialist, recently completed a six-month course offered by the New Jersey Healthcare Executive Leadership Academy (NJHELA). Two of just 22 participants, Balsamini and Freed were selected to take part in the 2019 NJHELA class, which seeks to build collaborative leadership skills among physicians and executives from both hospitals and health insurance companies. This year’s course focused on ways to address the opioid crisis in the state of New Jersey, with members developing and formally presenting projects that highlighted different aspects of this important issue and providing solutions to combat this crisis.
Balsamini and Freed were awarded a certificate of completion in Advanced Health Care Leadership from the program’s academic partner Seton Hall University. Dr. Balsamini attended the closing ceremony and reception on Friday, June 7 at the Nassau Inn in Princeton, NJ.
For more information about NJHELA and this year’s graduating class, visit www.njhela.com.